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CC BY-NC-ND license (http://creativeBackground: The Clinical and Laboratory Standards Institute (CLSI) revised the susceptibility
breakpoints of cephalosporins for Enterobacteriaceae in 2010 and 2011. However, there is a
lack of clinical data about the correlation of minimum inhibitory concentrations (MICs) and
clinical outcome. Data for the distribution of MICs and clinical outcomes were analyzed in this
study to evaluate the impact of changes in the CLSI breakpoints on the treatment of Klebsiella
pneumoniae bacteremia.
Methods: Ninety-seven bacteremic K. pneumoniae isolates from Taichung Veterans General
Hospital, Taichung, Taiwan were collected for study during the period 2009e2011. The cefazo-
lin MIC was determined by the broth microdilution method according to the recommendations
of the CLSI. The MIC distribution of cefazolin and the clinical responses to definitive cefazolin
treatment were analyzed.
Results: The modal cefazolin MIC among the 97 isolates was 1 mg/mL and accounted for 73
(75.3%) isolates. There were 18 (18.6%) isolates with a cefazolin MIC of 2 mg/mL. The conven-
tional dosage regimens of cefazolin (1 g every 6 hours or 8 hours) achieved a clinical cure in 70
(97.2%) of 72 patients in the group with a cefazolin MIC 1 mg/mL and in 14 (87.5%) of 16 pa-
tients in the group with a cefazolin MIC of 2 mg/mL. With the conventional dose, the cumula-
tive clinical cure rate for K. pneumoniae bacteremia with cefazolin MIC 2 mg/mL was 95.5%
(84/88 patients).fectious Diseases, Taichung Veterans General Hospital, Number 1650, Section 4, Taiwan Boulevard,
(Z.-Y. Shi).
.08.021
Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
680 C.-H. Chuang et al.Conclusion: The conventional cefazolin dose still can result in satisfactory clinical cure rates
for bacteremic episodes due to K. pneumoniae with cefazolin MIC 2 mg/mL, the revised sus-
ceptible breakpoint of CLSI 2011.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Klebsiella pneumoniae is a common pathogen that causes
urinary tract infections,1 biliary tract infections,2 liver ab-
scesses,3,4 pneumonia,5,6 and bacteremia.7 The reported
case fatality rates of K. pneumoniae bacteremia are
20e40%.4,8e10
Before 2010, the breakpoints of cephalosporins for
Enterobacteriaceae had been set for several decades.11 As
a result of the growing prevalence of extended spectrum
beta-lactamase (ESBL)-producing isolates around the
world,12,13 screening and confirmatory tests for ESBLs in K.
pneumoniae and Escherichia coli were developed by the
National Committee for Clinical Laboratory Standards in
1999.14 Based on an evaluation of the microbiological data,
clinical outcomes, and pharmacodynamic-pharmacokinetic
(PK-PD) properties for susceptibility breakpoints, the Clin-
ical and Laboratory Standards Institute (CLSI) performance
standards in 2010 revised the interpretive criteria for
cephalosporins and aztreonam.15 The minimum inhibitory
concentration (MIC) breakpoints for cefazolin were revised
in 2010: the susceptible breakpoint changed from
8 mg/mL to 1 mg/mL, the intermediate breakpoint from
16 mg/mL to 2 mg/mL, and the resistant breakpoint from
32 mg/mL to 4 mg/mL.15 However, using the CLSI
breakpoints published in 2010, the strains with cefazolin
MICs of 2e8 mg/mL are regarded as intermediate or resis-
tant to cefazolin. Consequently, this revision would pre-
clude the use of cefazolin, a conventionally effective drug,
for the prevention and treatment of infection caused by
Enterobacteriaceae that do not have a resistance mecha-
nism.11 To prevent this impact, the breakpoints of cefazolin
for Enterobacteriaceae was further revised by the CLSI in
2011 (susceptible, 2 mg/mL; intermediate, 4 mg/mL; and
resistant, 8 mg/mL), according to Monte Carlo simulations
of PK-PD data and recent laboratory data.11
To define the microbiological breakpoints which differ-
entiate wild-type strains from those with resistance
mechanisms, moderate to large numbers of in vitro MIC
tests are needed to provide the patterns of MIC distribu-
tion.11 However, there is a lack of data on the natural
antibiotic MIC distribution of K. pneumoniae.16,17 A few
published clinical studies on the treatment of urinary tract
infections caused by Enterobacteriaceae with cefazolin
have been conducted.18,19 The dose and frequency of the
regimen varied widely among the studies.18e21 Data about
the correlation of MIC and cephalosporin dose from clinical
trials are also lacking.18e21
We therefore conducted this study to evaluate the MIC
distribution of cefazolin among K. pneumoniae isolates, toanalyze the correlation of MICs and the clinical outcomes of
patients with K. pneumoniae bacteremia, and to analyze
the impact of cefazolin breakpoint changes of CLSI in 2011
on treatment.
Materials and methods
Bacterial strains
During the period from January 2009 to December 2011,
721 K. pneumoniae non-duplicate isolates from blood
specimens were identified at the Microbiology Laboratory
of Taichung Veterans General Hospital, Taichung, Taiwan.
The susceptibility tests of these isolates were performed by
the disk diffusion method and read according to the CLSI
2009 recommendations.22 There were 630 isolates suscep-
tible to cefazolin and 91 isolates resistant to cefazolin
(using the disk diffusion test, including the double-disk
diffusion method of the CLSI 2009 ESBL confirmatory
test22). The medical records were reviewed for all 721 pa-
tients with K. pneumoniae bacteremia. Only 97 patients
with bacteremia due to cefazolin-susceptible isolates (disk
diffusion test, CLSI 200922) were included with the condi-
tion that cefazolin had been initiated within 2 days of the
report of K. pneumoniae bacteremia and used for at least 7
days. These 97 isolates were selected for the MIC study.
Among 91 cefazolin-resistant isolates, only 82 isolates were
available for MIC tests.
Susceptibility test
The cefazolin MICs were measured by the broth micro-
dilution method according to the CLSI recommendations.23
E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853 were used as the quality control strains. The sus-
ceptibility breakpoints of cefazolin were 8 mg/mL,
1 mg/mL, 2 mg/mL, according to the CLSI recommen-
dations issued in 2009,22 2010,15 and 2011,28 respectively.
Clinical and bacteriological assessments
The clinical outcomes of the 179 patients with bacteremia
of K. pneumoniae (97 cefazolin-susceptible and 82
cefazolin-resistant, selected by the disk diffusion tests
according to CLSI 200922) were analyzed by a review of the
medical records. The clinical conditions (such as age, sex,
source of infection, length of stay, days to defervescence
after antimicrobial treatment, clinical response, and
death) associated with the acquisition of K. pneumoniae
Figure 1. Minimum inhibitory concentration (MIC) distribu-
tion of cefazolin and correlated rates of clinical cure among
the 97 Klebsiella pneumoniae isolates included in the study.
Cefazolin minimum inhibitory concentrations 681bacteremia were reviewed. The efficacy was assessed by
the clinical and bacteriological response.24 The clinical
response was evaluated at the end of antimicrobial treat-
ment and defined as cure (disappearance of acute signs and
symptoms related to the infection or sufficient improve-
ment such that additional or alternative antimicrobial
treatment was not required), failure (insufficient
improvement of the signs and symptoms of infection and
additional or alternative antimicrobial treatment was
required), or indeterminate (a clinical assessment was not
possible for any reason). The bacteriological response was
evaluated at the 7th day after the discontinuation of anti-
microbial treatment and defined as eradication (no more
positive blood cultures yielded), presumed eradication
(absence of evaluable culture in a patient with clinical
cure), persistence (presence of baseline pathogen in a pa-
tient with clinical failure of treatment), presumed persis-
tence (absence of evaluable culture in a patient with
clinical failure of treatment), or indeterminate (if bacte-
riological response was not evaluable for any reason).
Bacteriological success was defined if eradication or pre-
sumed eradication were present. Bacteriological failure
was rated as persistence or presumed persistence. The 14-
day mortality rates after bacteremia were analyzed.
The clinical characteristics and outcomes of these 97
patients with K. pneumoniae bacteremia were classified
into three groups according to cefazolin MICs: 1 mg/mL,
2 mg/mL, and 4e8 mg/mL.
Statistical analysis
Categorical variables were analyzed by two-tailed c2 test;
continuous variables were analyzed by the Student t test
and analysis of variance test. p < 0.05 was considered
statistically significant. All statistical analyses were per-
formed with SPSS version 22.0.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
During the study period, 97 clinically evaluable patients with
cefazolin-susceptible K. pneumoniae bacteremia were
treated with cefazolin. The MICs for the 97 isolates were
8 mg/mL, including 1 mg/mL for 75 (77.3%) isolates, 2 mg/
mL for 18 (18.6%) isolates, and 4e8 mg/mL for four (4.1%)
isolates (Fig. 1). The clinical characteristics and outcomes of
97 patients with K. pneumoniae bacteremia (classified into
three groups, cefazolin MIC1 mg/mL, 2 mg/mL, and 4e8 mg/
mL) are given in Table 1. Therewas no statistically significant
difference in the demographic characteristics and outcomes
among the three groups, except for skin and soft tissue
infection and length of stay in hospital. The length of stay in
hospital in the three groups of cefazolin MIC1 mg/mL, 2 mg/
mL, and 4e8 mg/mL were 17  1.1 days, 25  3.5 days, and
34  9.6 days, respectively. There were statistically signifi-
cant differences in the length of stay among these three
groups (p< 0.05). The patients in the groupwith a higher MIC
had longer lengths of stay (p < 0.05). The periods to defer-
vescence in the three groups of cefazolin MIC 1 mg/mL,
2 mg/mL, and 4e8 mg/mLwere 2.2 0.1 days, 1.3 0.1 days,
and 1.6 0.3 days, respectively (pZ 0.056). The duration oftreatment in the three groups of cefazolin MIC 1 mg/mL,
2 mg/mL, and 4e8 mg/mL were 12.8  0.7 days, 14.3  2.3
days, and 15  3.2 days, respectively (pZ 0.634).
There were 25 patients with K. pneumoniae bacteremia
and liver abscess. Among 25 isolates from patients with
liver abscess, there were 20 isolates with cefazolin MIC
1 mg/mL, four isolates with a cefazolin MIC of 2 mg/mL,
and one isolate with a cefazolin MIC of 4 mg/mL. All patients
with K. pneumoniae bacteremia and liver abscess were
clinically cured.
All 97 isolates were negative for the double-disk diffusion
method of the ESBL confirmatory test. The modal cefazolin
MIC was 1 mg/mL and accounted for 73 (75.3%) isolates. The
cumulative percentage for MIC 2 mg/mL was 95.9%.
Cefazolin MICs of 82 cefazolin-resistant isolates (by disk
diffusion test, CLSI 200922) ranged from 16 mg/mL to
>256 mg/mL, including 16 mg/mL for two isolates; 32 mg/mL
forfive isolates; 64mg/mLforone isolate;128mg/mLfor seven
isolates; 256 mg/mL for two isolates; and >256 mg/mL for 65
(79.3%) isolates. The 82 patients with cefazolin-resistant K.
pneumoniae bacteremia were treated with carbapenem,
fluoroquinolones, or third-generation cephalosporins.
The rates of clinical cure were 97% (73/75), 88.9% (16/
18), 100% (3/3), and 100% (1/1) for the patients in the
groups with cefazolin MICs of 1 mg/mL, 2 mg/mL, 4 mg/mL,
and 8 mg/mL, respectively (Fig. 1). Table 2 gives the rates
of clinical cure correlated with the MIC and dosage
regimen. Among 72 patients in the group with cefazolin MIC
1 mg/mL and treated with the conventional dose (cefa-
zolin given as 1 g every 6 hours or 8 hours), the rate of
clinical cure was 97.2%. During antimicrobial treatment,
one patient died as a result of arrhythmia with sudden
death and the other died from terminal lung cancer with
multiple organ failure. Although clinical improvement was
observed in these two patients, clinical cure was not ach-
ieved due to death before the end of the scheduled anti-
microbial treatment. Among 16 patients in the group with a
cefazolin MIC of 2 mg/mL and treated with the conventional
dose (cefazolin given as 1 g every 6 hours or 8 hours), the
rate of clinical cure was 87.5% (14/16 patients). Two pa-
tients died from liver cirrhosis and lung cancer with mul-
tiple organ failure, respectively, before the end of the
scheduled antimicrobial treatment.
Table 1 Comparison of clinical characteristics and outcomes of 97 patients with Klebsiella pneumoniae bacteremia, classified
by cefazolin minimum inhibitory concentration of the bacteremic isolate: 1 mg/mL, 2 mg/mL, and 4e8 mg/mL
Clinical characteristic Cefazolin MIC (mg/mL) p
1 (n Z 75) 2 (n Z 18) 4e8 (n Z 4)
Age (y) 62  12.8 65  13.7 80  13.2 0.089
Male sex 50 (66.7) 13 (72.2) 3 (75.0) 0.926
Source of infection
Intra-abdominal infection 50 (66.7) 11 (61.1) 2 (50.0) 0.492
Liver abscess 20 (26.7) 4 (22.2) 1 (25.0) 0.625
Skin and soft tissue infection 1 (1.3) 0 (0.0) 1 (25.0) <0.05
Urinary tract infection 10 (13.3) 7 (38.8) 0 (0.0) 0.051
Central line related 0 (0.0) 1 (5.5) 0 (0.0) 0.142
Unknown 14 (18.6) 1 (5.5) 1 (25.0) 0.299
Length of stay in hospital (d) 17  1.1 25  3.5 34  9.6 <0.05
Time to defervescence (d) 2.2  0.1 1.3  0.1 1.6  0.3 0.056
Treatment duration (d) 12.8  0.7 14.3  2.3 15.1  3.2 0.634
Co-morbidity
Liver function impairment 34 (45.3) 8 (44.4) 0 (0.0) 0.191
Renal insufficiency 9 (12.0) 1 (5.5) 3 (75.0) <0.05
Heart failure 8 (10.6) 1 (5.5) 1 (25.0) 0.463
Diabetes mellitus 29 (38.6) 5 (27.7) 3 (75.0) 0.152
Malignancy 28 (37.3) 7 (38.8) 0 (0.0) 0.312
Absolute neutrophil count <500/mm3 3 (4.0) 0 (0.0) 0 (0.0) 0.613
Immunosuppression treatment 13 (17.3) 4 (22.2) 0 (0.0) 0.633
14-day mortality 2 (2.6) 2 (11.1) 0 (0.0) 0.321
Data are presented as n (%) or mean  standard deviation.
MIC Z minimum inhibitory concentration.
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hours as a result of renal insufficiency and one patient with
cefazolin 0.5 g every day as a result of uremia. The
bacteriological success rate was 100% for all 93 patients
with a complete course of treatment with cefazolin. The
patients in the group with cefazolin MIC 8 mg/mL had a
lower 14-day mortality rate than those in the group with
cefazolin MIC >8 mg/mL (4.1% vs. 47.5%; p < 0.001).Discussion
The breakpoints of cefazolin for Enterobacteriaceae
revised by the CLSI in 201015 were 1 mg/mL as susceptible,Table 2 Clinical cure rates categorized by cefazolin minimum
dosage among 97 patients with Klebsiella pneumoniae bacterem
Cefazolin MIC (mg/mL)
Normal renal function
1g Q6H 1g Q8H
0.25 0/1 (0)
0.5 1/1 (100)
1 40/40 (100) 29/30 (
2 8/10 (80) 6/6 (10
4 2/2 (10
8 1/1 (10
a Q6H Z every 6 hours; Q8H Z every 8 hours; Q12H Z every 12 ho
Data are presented as n (%).
MIC Z minimum inhibitory concentration.2 mg/mL intermediate, and 4 mg/mL resistant. Accordingly
22 (22.7%) of 97 isolates with cefazolin MICs of 2e8 mg/mL
in the current study would fall into the intermediate or
resistant categories. However, the clinical outcome of
these 22 patients was evaluated as achieving clinical cure
and bacteriological eradication, arguing for the latest sus-
ceptible breakpoint of cefazolin, i.e., 2 mg/mL.
From the viewpoint of the microbiological data, the
modal cefazolin MIC among 97 cefazolin-susceptible isolates
in this study was 1 mg/mL and accounted for 73 (75.3%) iso-
lates. The cumulative percentage for MIC 2 mg/mL was
95.9%. If the susceptibility breakpoint was 1 mg/mL (CLSI
201015), 18.6% of isolates with MIC of 2 mg/mL would be
interpreted as intermediate. This would result in a greatinhibitory concentration of bacteremic isolates and cefazolin
ia (MIC  8 mg/mL)
Cefazolin dose a
Renal insufficiency Hemodialysis
1g Q12H 0.5g QD
97.6) 2/2 (100) 1/1 (100)
0) 2/2 (100)
0) 1/1 (100)
0)
urs; QD Z every day.
Cefazolin minimum inhibitory concentrations 683impact on the choice of cefazolin for the treatment of
Enterobacteriaceae infections. Hence, we examined data
from other studies before interpretating our data. The MIC
distribution ofwild-typemicroorganisms are available on the
EUCASTwebsite.25 Of 208 wild-type K. pneumoniae isolates,
there were 71 (34.1%) isolates had a cefazolin MIC of 1 mg/mL
and 82 (39.4%) isolates had an MIC of 2 mg/mL. The cumula-
tive percentage for MIC 2 mg/mL was 73.6%. In another
study conducted in theMayo Clinic (Rochester, MN, USA), 199
consecutive clinical isolates of E. coli (n Z 180), K. pneu-
moniae (n Z 8), and Klebsiella oxytoca (n Z 11) were
studied for their cephalosporin MIC.16 Among the 191 isolates
without acquired secondary b-lactamases (ESBL or AmpC),
there were 34 (17.8%) isolates with a cefazolin MIC of 1 mg/
mL and 98 (51.3%) isolates with a cefazolin MIC of 2 mg/mL.16
The cumulative percentage forMIC2 mg/mLwas 69.1%. The
cumulative percentages of the isolates with MIC 2 mg/mL
ranged from 69.1% to 95.9%, accounting for the majority of
isolates without a resistance mechanism in these three
studies. Hence it is reasonable to revise the interpretive
criteria of cefazolin from 1 mg/mL (CLSI 201015) to 2 mg/mL
(CLSI 201128) based on these microbiological data.
According to PK-PD data, the cefazolin susceptibility
breakpoint of 2 mg/mL based on a higher dosage regimen (2 g
every 8 hours) was suggested by CLSI 2011.28 The decision for
the revised breakpoints by CLSI 201128 was based on the
Monte Carlo simulation analysis.26,27 The target attainment
rates for 50% T > MIC can achieve 94% for the isolates with a
cefazolin MIC of 1 mg/mL and 64% for those of 2 mg/mL at the
conventional dose regimen of 1 g every 8 hours.26 Therefore
the susceptibility breakpoint of cefazolin was determined as
1 mg/mL for the conventional dose regimen (1 g every 8
hours) by CLSI 2010.15 However, the target attainment rates
would achieve 100% for the isolates with a cefazolin MIC of
1 mg/mL and 94% for those of 2 mg/mL at a higher cefazolin
dose (2 g every 8 hours).26 Therefore the interpretive criteria
for cefazolin in the CLSI 201128 were revised (susceptible,
2 mg/mL; intermediate, 4 mg/mL; and resistant,8 mg/mL)
based on a higher dose regimen.
The clinical outcome data, as well as the microbiological
data, should be evaluated to determine the optimum sus-
ceptibility breakpoint of cefazolin. The conventional dose
regimens of cefazolin (1 g every 6 hours or 8 hours) ach-
ieved clinical cure in 97.2% of 72 patients in the group with
a cefazolin MIC 1 mg/mL and in 87.5% of 16 patients in the
group with a cefazolin MIC of 2 mg/mL. With conventional
doses, the rate of clinical cure for bacteremia of K. pneu-
moniae with cefazolin MIC 2 mg/mL was 95.5%. Such study
findings can support the revised cefazolin susceptibility
breakpoint of 2 mg/mL (CLSI 201128).
There were some limitations in this study. First, a rela-
tively small number of patients, especially those in the
group with a cefazolin MIC of 4e8 mg/mL, was not sufficient
to demonstrate significant associations between cefazolin
MIC and clinical outcome, although they were successfully
treated with cefazolin. Second, the 30-day mortality was
not analyzed, because the patients were treated with a
mean duration of 13.1 days and a mean hospital stay of 20.3
days. Third, although clinical cure was achieved in all 25
patients with liver abscess and cefazolin treatment, the
number of patients was limited and this study focused on
the clinical response of definitive cefazolin treatmentwithout the inclusion of critically ill patients. Cefazolin in
conventional dose regimens has been used for liver abscess
for decades.29 The role of cefazolin treatment for systemic
infections due to K. pneumoniae with cefazolin MIC 2 mg/
mL warrants further clinical studies.
In conclusion, conventional cefazolin dosage (1 g every 6
hours or 8 hours) can result in satisfactory clinical cure
rates of bacteremic episodes due to K. pneumoniae with
cefazolin MIC 2 mg/mL. Such clinical data argue for the
latest cefazolin-susceptible breakpoint of 2 mg/mL based
on a higher dose regimen.Conflicts of interest
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